Showing results (1781-1790 of 1,881) with videos related to

Sort By:
Pageof 189
The Lancet. Microbe|August 7, 2023
Comparative antibody and cell-mediated immune responses, reactogenicity, and efficacy of homologous and heterologous boosting with CoronaVac and BNT162b2 (Cobovax): an open-label, randomised trialNancy H L Leung, Samuel M S Cheng, Carolyn A Cohen, et al.
The Spine Journal : Official Journal of the North American Spine Society|March 28, 2025
Guideline summary review: an evidence-based clinical guideline for the diagnosis and treatment of adults with neoplastic vertebral fracturesCharles H Cho, Steven W Hwang, Daniel J Mazanec, et al.
Nature Communications|January 20, 2019
Aberrant enhancer hypomethylation contributes to hepatic carcinogenesis through global transcriptional reprogrammingLei Xiong, Feng Wu, Qiong Wu, et al.
Cell Reports|May 23, 2019
c-Myb Exacerbates Atherosclerosis through Regulation of Protective IgM-Producing Antibody-Secreting CellsEric A Shikatani, Rickvinder Besla, Sherine Ensan, et al.
Clinical Kidney Journal|March 24, 2025
Humoral and cellular immunogenicity of a fourth dose BNT162b2 in children with chronic kidney diseasesJeffery C H Chan, Eugene Yu-Hin Chan, Samuel M S Cheng, et al.
Kidney International Reports|November 29, 2023
Humoral and Cellular Immunogenicity of 3 Doses of BNT162b2 in Children With Kidney DiseasesDaniel Leung, Eugene Yu-Hin Chan, Xiaofeng Mu, et al.
Nature Communications|June 28, 2022
Immunogenicity and reactogenicity of SARS-CoV-2 vaccines BNT162b2 and CoronaVac in healthy adolescentsJaime S Rosa Duque, Xiwei Wang, Daniel Leung, et al.
Signal Transduction and Targeted Therapy|December 14, 2022
Antibody and T cell responses against wild-type and Omicron SARS-CoV-2 after third-dose BNT162b2 in adolescentsXiaofeng Mu, Carolyn A Cohen, Daniel Leung, et al.
Nature Communications|August 26, 2024
A single-dose intranasal live-attenuated codon deoptimized vaccine provides broad protection against SARS-CoV-2 and its variantsXiang Liu, Wern Hann Ng, Eva Zusinaite, et al.
Frontiers in Immunology|October 7, 2022
Safety and immunogenicity of 3 doses of BNT162b2 and CoronaVac in children and adults with inborn errors of immunityDaniel Leung, Xiaofeng Mu, Jaime S Rosa Duque, et al.
Pageof 189